Pneumococcal vaccine

Pneumococcal vaccine
Type	Bacterial vaccine
Target	Streptococcus pneumoniae
Trade names	Prevnar 13, Pneumovax 23, Vaxneuvance, Prevnar 20
MedlinePlus	a607022
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intramuscular injection, Subcutaneous injection
ATCCode prefix	J07AL
ATCCode suffix	01, 02, 52
Legal status	US: ℞-only

Pneumococcal vaccine. These immunizations are designed to protect against infections caused by the bacterium Streptococcus pneumoniae, a major cause of pneumonia, meningitis, and sepsis. The World Health Organization lists them as essential medicines, and their development has been a significant achievement in preventive medicine. Vaccination programs have substantially reduced the incidence of invasive pneumococcal disease across numerous populations globally.

Types of pneumococcal vaccines

Two primary classes exist: polysaccharide vaccines and conjugate vaccines. The Pneumovax 23 is a prominent polysaccharide vaccine covering 23 serotypes, while conjugate vaccines like Prevnar 13 and the newer Prevnar 20 link the polysaccharide to a protein carrier. The development of Vaxneuvance represents an advancement in conjugate technology, designed to elicit a broader immune response. Research at institutions like the Walter Reed Army Institute of Research has contributed to these formulations.

Medical uses

These vaccines are indicated for the prevention of pneumococcal pneumonia and bacteremia in both children and adults. Key target groups include infants, older adults over age 65, and individuals with chronic conditions such as HIV/AIDS or sickle cell disease. The Advisory Committee on Immunization Practices provides guidelines for use, and they are a cornerstone of public health strategy by the Centers for Disease Control and Prevention. Vaccination is also recommended for patients undergoing splenectomy or receiving immunosuppressive therapy.

Administration and schedule

Administration is typically via intramuscular injection, though Pneumovax 23 can be given subcutaneously. For infants, the CDC schedule often involves a series of doses at 2 months, 4 months, 6 months, and a booster between 12 and 15 months. Adults may receive a single dose of conjugate vaccine followed by Pneumovax 23. Specific protocols can vary based on recommendations from bodies like the National Health Service or the American Academy of Pediatrics.

Efficacy and impact

Clinical trials and post-marketing surveillance have demonstrated high efficacy against invasive pneumococcal disease caused by vaccine serotypes. The introduction of Prevnar 7 in the United States led to a dramatic decline in disease incidence among children, a phenomenon documented by the Active Bacterial Core surveillance program. Studies published in journals like The New England Journal of Medicine have shown significant reductions in hospitalization rates and antibiotic resistance patterns following widespread vaccination.

Side effects and safety

Common reactions include pain at injection site, erythema, and low-grade fever. Serious adverse events like anaphylaxis are rare, and safety is continuously monitored by systems such as the Vaccine Adverse Event Reporting System. The Global Advisory Committee on Vaccine Safety reviews data to ensure benefit-risk profiles remain favorable. Contraindications include severe allergy to any vaccine component, as noted in labeling by the U.S. Food and Drug Administration.

History and development

Early work on a pneumococcal vaccine began in the early 20th century, with pivotal research by Almroth Wright and later Robert Austrian. The first licensed polysaccharide vaccine was developed in the 1970s. The breakthrough conjugate vaccine technology, pioneered for Haemophilus influenzae type b by John B. Robbins and Rachel Schneerson, was adapted for pneumococcus, leading to the approval of Prevnar 7 in 2000. Subsequent expansions in serotype coverage have been driven by pharmaceutical companies like Pfizer and Merck & Co..

Category:Vaccines Category:World Health Organization essential medicines